Risk of Nerve Damage After Administration of Local Anesthesia
ConditionInferior Alveolar Nerve Injuries
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorCleveland Dental Institute
About this trial
This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with age between 18-55 years old
Patients need IANB
healthy patient
Disqualifiers
medical conditions
allergies
medications
pregnancy and breastfeeding
Trial design
Design model
Parallel
Treatments tested in this trial
4% Articaine with 1:200,000 epinephrine
DrugInferior Alveolar Nerve Block with 4% articaine
2% lidocaine with 1:100,000 epinephrine
DrugInferior Alveolar Nerve Block with 2% lidocaine
Treatment groups
80 Participants
are divided into 2 treatment groupsGroup A: ArticaineExperimental treatment 1 intervention
Group B: LidocaineActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Electromyograph
Signs of loss of sensation in the involved side of the jaw will be recorded using a tool called Electromyograph machine to evaluate and record Nerve conduction velocity, the scale is as follow Normal (grade 0) to extremely damage of (grade 6) while a patient rate pain intensity on a Visual Analogue Scale (VAS).
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov